Overview

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Status:
Completed
Trial end date:
2013-01-10
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. It is not yet known which androgen suppression regimen is more effective for prostate cancer. PURPOSE: This randomized phase III trial is studying two hormone therapy regimens and comparing them to see how well they work in treating patients with rising PSA levels following radiation therapy for prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborators:
National Cancer Institute (NCI)
Southwest Oncology Group
Treatments:
Androgens
Bicalutamide
Buserelin
Cyproterone
Cyproterone Acetate
Flutamide
Goserelin
Hormones
Leuprolide
Nilutamide